UZ Leuven

Abdominale heelkunde

• Perineal colostomy with antegrade continence enemas as an alternative after abdominoperineal resection for low rectal cancer. Penninckx F, D’Hoore A, Vandenbosch A. Ann Chir 2005;130:327-330.
• Cancer cell dissemination during curative surgery for colorectal liver metastases. Topal B Aerts JL, Roskams T, Fieuws S, Van Pelt J, Vandekerckhove P, Penninckx F. Eur J Surg Oncol 2005;31:506-511.
• Aggregated colon cancer cells have a higher metastatic efficiency in the liver compared with non aggregated cells: an experimental study. Topal B, Roskams T, Fevery J, Penninckx F. J Surg Res 2003;112: 31-37.
• Patterns of failure following curative resection of colorectal liver metastases. Topal B, Kaufman L, Aerts R, Penninckx F.Eur J Surg Oncol 2003;29:248-253.
• Laparoscopic radiofrequency ablation of unresectable liver malignancies: feasibility and clinical outcome. Topal B, Aerts R, Penninckx F. Surg Laparosc Endosc Percutan Tech 2003;13: 11-15.

Abstracts

Top

Abdominale transplantchirurgie

• Early presence of regulatory cells in transplanted rats rendered tolerant by donor-specific blood transfusion. Kitade H, Kawai M, Rutgeerts O, Landuyt W, Waer M, Mathieu C, Pirenne J.J Immunol 2005;175:4963-4970.
• Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Kawai M, Kitade H, Mathieu C, Waer M, Pirenne J.Transplantation 2005;79:1073-1077.
• Combined “en bloc” liver and pancreas transplantation in patients with liver disease and type 1 diabetes mellitus. Pirenne J, Deloose K, Coosemans W, Aerts R, Van Gelder F, Kuypers D, Maes B, Verslype C, Yap P, Van Steenbergen W, Roskams T, Mathieu C, Fevery J, Nevens F. Am J Transplant 2004;4:1921-1927.
• Tolerance of liver transplant patients to strenuous physical activity in high-altitude. Pirenne J Van Gelder F, Kharkevitch T, Nevens F, Verslype C, Peetermans WE, Kitade H, Vanhees L, Devos Y, Hauser M, Hamoir E, Noizat-Pirenne F, Pirotte B.Am J Transplant 2004;4:554-560.
• Livers from non-heart-beating donors tolerate short periods of warm ischemia. Monbaliu D, Crabbé T, Roskams T, Fevery J, Verwaest C, Pirenne J.Transplantation 2005;79:1226-1230.

Abstracts

Top

Algemene medische oncologie

• Standard chemotherapy with or without high-dose chemotherapy for aggressive non-hodgkin’s lymphoma : randomized phase III EORTC study. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM, Musson H, Teodorovic I, Maes B, Carbone A, Carde P, Thomas J. J Natl Cancer Inst 2001;93(1):22-30.
• Pharmacology of anticancer drugs in the elderly population. Wildiers H, Highley MS, de Bruijn E, van Oosterom AT. Clin Pharmacokinet 2003;42(14):1213-1242.

• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Lancet 2004;364(9440):1127-34.

• Breast International Group (BIG) 1-98 Collaborative Group. Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. NEJM 2005;353(26):2747-57.
• In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking. Dumez H, Guetens G, De Boeck G, Highley MS, de Bruijn EA, van Oosterom AT, Maes RAA. Anti Cancer Drugs 2005;16:893-895.

Top

Abstracts

Centrum voor Menselijke Erfelijkheid

• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. Cools J, DeAngelo DJ, et al.N Engl J Med 2003;348(13):1201-14.
• Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A and Marynen P. Gastroenterology 2005;128(2): 270-9.
• Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Graux C, Cools J et al Nat Genet 2004;36(10):1084-9.
• Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pauwels P, De Wever I, Vermeesch JR, de Raedt T, De Paepe A, Speleman F, van Oosterom A, Messiaen L and Legius E.Hum Mol Genet 2006;15(6):1015-23.
• Clinical and molecular features of FIP1L1-PDFGRA (+) chronic osinophilic leukemias. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, agemeijer A and Marynen P. Leukemia 2004;18(4):734-42.
• Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Wlodarska I, Nooyen P, Maes B, Martin-Subero JI, Siebert R, et al. Blood 2003;101(2): 706-10.

Abstracts

Top

Digestieve oncologie

• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E.N Engl J Med 2004; 351:1337-1345.
• Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. Van Cutsem E, Van De Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schöffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D.J Clin Oncol 2004; 22: 1430-1438.
• Capecitabine: Bridging the atlantic divide in colon cancer treatment.Van Cutsem E, Verslype C, Tejpar S.Oral Semin Oncol 2005;32:43-51.
• Recommendations on adjuvant chemotherapy for stage II colon cancer. Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG.
• Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. Flamen P, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L. J Clin Oncol 2000;18:3202-3210.
• Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Van Schaeybroeck S, Karaiskou-Mccaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P. Clin Cancer Res. 2005;11(20):7480-7849.
• Tcf-3 expression and ?-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumor). Tejpar S, Li C, Yu C, Poon R, Denys H, Sciot R, Van Cutsem E, Cassiman JJ, Alman BA. Brit J Cancer 2001;85:98-101.
• ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of advanced colon cancer. Van Cutsem E, Oliveira J, Kataja VV, coordinating authors for the ESMO Guidelines Task Force. Ann Oncol 2005;16:i18-i19.

Abstracts

Top

Dermatologie

• A low UVB dose, with the potential to trigger a protective p53-dependent geneprogram, increases the resilience of keratinocytes against future UVB insults. Decraene D, Smaers K, Maes D, Matsui M, Declercq L, Garmyn M. J Invest Dermatol 2005;125(5):1026-31.
• Casecontrol study to identify melanoma risk factors in the Belgian population: the significance of clinical examination. Nijsten T, Leys C, Verbruggen K, Verlinden V, Drieghe J, Stas M, Lambert J, DeGreef H, Garmyn M. J Eur Acad Dermatol Venereol 2005;19(3):332-9.
• AKT status controls susceptibility of malignant keratinocytes to the early-activated and UVB-induced apoptotic pathway. Decraene D, Van Laethem A, Agostinis P, De Peuter L, Degreef H, Bouillon R, Garmyn M. J Invest Dermatol 2004;123(1):207-12.
• A synthetic superoxide dismutase/catalase mimetic (EUK-134) inhibits membrane-damage-induced activation of mitogen-activated protein kinase pathways and reduces p53 accumulation in ultraviolet B-exposed primary human keratinocytes. Decraene D, Smaers K, Gan D, Mammone T, Matsui M, Maes D, Declercq L, Garmyn M. J Invest Dermatol 2004;122(2):484-91.
• Insulin-like growth factor-1-mediated AKT activation postpones the onset of ultraviolet B-induced apoptosis, providing more time for cyclobutane thymine dimer removal in primary human keratinocytes. Decraene D, Agostinis P, Bouillon R, Degreef H, Garmyn M. J Biol Chem 2002;277(36):32587-95. Epub 2002 Jun 17.

Abstracts

Top

Endocrinologie

• The Group for Lanreotide Autogel Long-Term Study on Acromegaly. One-year followup of patients with acromegaly treated with fixed or titrated doses of Lanreotide Autogel. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ. Clin Endocrinol (Oxf) 2004;60(6):734-40.
• Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. NN703 Clinical Research Group. Svensson J, Monson JP, Vetter T, Hansen TK, Savine R, Kann P, Bex M, Reincke M, Hagen C, Beckers A, Ilondo MM, Zdravkovic M, Bengtsson BA, Korbonits M;Clin Endocrinol (Oxf) 2003;58(5):572-80.
• The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. J Bone Miner Res 2002;17(6):1081-94.
• Characterization of the condensin component Cnap1 and the protein kinase Melk as novel E2F-target genes downregulated by 1,25-dihydroxyvitamin D3. Verlinden L, Eelen G, Beullens I, Van Camp M, Van Hummelen P, Engelen K, Van Hellemont R, Marchal K, De Moor B, Foijer F, Te Riele H, Beullens M, Bollen M, Mathieu C, Bouillon R, Verstuyf A. J Biol Chem 2005;280:37319-37330.
• Previtamin D3 with a trans-fused decalin CD-ring has pronounced genomic activity. Verlinden L, Verstuyf A, Verboven C, Eelen G, De Ranter C, Gao L-J, Murad I, Choi M, Yamamoto K, Yamada S, Van Haver D, Vandewalle M, De Clercq PJ, Bouillon R. J Biol Chem 2003;278(37):35476-35482.

Abstracts

Top

Gynaecologische Oncologie

• Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, et al.Lancet 2001;357:176-82.
• Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli SJ Natl Ca Instit 2003;95:113-25.
• Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Limbergen E, Berteloot P, Amant F, Vergote I and Christiaens MR. Ann Oncol 2005;16:1755-61.
• Endometrial cancer. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I.Lancet 2005;366:491-505.
• In utero exposure to chemotherapy: effect on cardiac and neurological outcome. Van Calsteren K, Ganame J, Lagae L, Delforge M, Berteloot P, Paridaens R, Noens L, Humblet Y, Vandermeersch B, De Muylder X, Claus P, Hanssens M, Vergote I, Mertens L, Amant F. J Clin Oncol 2006;24:e16-7
• Vergote I, Tropé C, Amant F et al Neoadjuvant chemotherapy or primary surgery in Stage IIIc-IV ovarian cancer, NEJM in press.
• Vergote I, Pujade-Lauraine E, Pignata S, et al. European Network of Gynaecological Oncological Trial Groups.  European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies. Int J Gynecol Cancer. 2010 Apr;20(3):476-8.
• Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphazizing the obstetrical and neonatal outcomes. J. Clin Oncol. 2010 Feb 1; 28(4): 683-9
• Leunen K, Gevaert O, Daemen A, et al. Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways. Hum Mutat. 2009 Dec;30(12):1693-702.
• Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009 Dec;10(12):1188-98.

Abstracts

Top

Hematologie

• CD34+ marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of a4ß1 and a5ß1 integrins. Delforge M, Raets V, Van Duppen V, Vandenberghe P, Boogaerts M. Leukemia 2005;19:57-63.
• Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, DePauw BE. N Engl J Med 2004; 351:1391-402.
• A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs. from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Cornelissen JJ, van der Holt B, Petersen EJ, Vindelov L, Russel CA, Hoglund M, Maertens J, Schouten HC, Braakman E, Steijaert MM, Zijlmans MJ, Slaper-Cortenbach I, Boogaerts MA, Lowenberg B, Verdonck LF.
• Additional prognostic value of bone marrow histology in patients subclassified according to the international prognostic scoring system for myelodysplastic syndromes. Verburgh E, Achten R, Maes B, Hagemeijer A, Boogaerts M, De Wolf-Peeters C, Verhoef G.J ClinOncol 2003;21:273-282.
• Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukaemia. Löwenberg B, Van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P, Fey M, Schouten H, de Greef G, Ferrant A, Kovacsovics T, Gratwohl A, Daenen S, Huijgens P, Boogaerts M. N Engl J Med 2003;349:743-752.
• The value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Ossenkoppele G, Graveland W, Sonneveld P, Daenen S, Biesma D, Verdonck L, Schaafsma M, Westveer P, Peters G, Noordhuis P, Muus P, van de Holt B, Delforge M, Lowenberg B, and Verhoef G. Blood 2004;103: 2908-2913.

Abstracts

Top

Kindergeneeskunde

• Children’s Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased- risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, et al. J Clin Oncol 2001;19(7):1935-42.
• Aberrant lysosomal carbohydrate storage accompanies endocytic defects and neurodegeneration in Drosophila benchwarmer. Dermaut B, Norga K, Kania A, Verstreken P, Pan H, Zhou Y, Callaerts P, Bellen HJ. J Cell Biol 2005;170(1):127-39.
• The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. Freson K, Hashimoto H, Thys C, Wittevrongel C, Danloy S, Morita Y, et al.J Clin Invest 2004;113(6):905-12.
• Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A, et al. EORTC-CLG. Blood 2004;103(2):442-50.

Abstracts

Multidisciplinair borstcentrum

• The requirements of a specialist Breast Unit. Perry N, Wilson A, Ellis I, Blichert-Toft M, Rosselli del Turco M, Garas I, Greco M, Julien JP, Christiaens R, van de Velde C, Holland R, Elston C, Pentek Z, Cataliotti L. Eur J Cancer 2000;36:2288-2293.
• Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using realtime quantitative revers transcription-PCR. Ismail MS, Wynendaele W, Aerts JLE, Paridaens R, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Wildiers H, Omar S, Vandekerckhove P, Van Oosterom AT. Clin Cancer Res 2004;10:196-201.
• Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment. Smeets A, Christiaens MR. Curr Opin Oncol 2005;17(6):539-544.
• Association between tumour characteristics and HER-2/neu by immunohostochemistry in 1362 women with primary operable breast cancer. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen Eric, Berteloot P, Amant F, Vergote I, Christiaens MR. J Clin Pathol 2005;58:611–616.

Abstracts

Top

Neurochirurgie

• Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, interobserver variability and prognostic value. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L. Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):39-51.
• Surgery and adjuvant dendritic cellbased tumour vaccination for patients with relapsed malignant glioma, a feasibility study. De Vleeschouwer S, Rutkowski S, Kaempgen E, Wolff JE, Kuhl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sorensen N, Opitz A, Van Gool SW. Br J Cancer. 2004,91,1656-1662.
• Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. De Vleeschouwer S, Arredouani M, Ade M, Cadot P, Vermassen E, Ceuppens JL, Van Gool SW. Cancer Immunol Immunother 2005;54:372-82. 
• Lhermitte- Duclos disease: 11 C-methionine positron emission tomography data in 4 patients.Van Calenbergh F, Vantomme N, Flamen P, Demaerel P, Sciot R, Legius E, Mortelmans L, Plets C. Surg. Neurol 2006;65:293-296.

Abstracts

Top

Neus- Keel- en Oorziekten

• Laryngeal repair after resection of advanced cancer: an optimal reconstructive protocol. Delaere P, Vander Poorten V, Vranckx J, Hierner R.Eur Arch Otolaryngol 2005;262:910-6.
• Tracheal autotransplantation as a new and reliable technique for the functional treatment of advanced laryngeal cancer. Delaere P, Hermans R. Laryngoscope 2003;113:1244-51.
• The development of a prognostic score for patients with parotid carcinoma. Vander Poorten VLM, Balm AJM, Hilgers FJM, Tan IB, Loftus Coll BM, van Leeuwen FE, Hart AAM.
• Prognostic index of patients with parotid carcinoma: external validation using the 1985-1994 Dutch Head and Neck Oncology Cooperative Group Database. Vander Poorten V, Hart AAM, van der Laan BFAM,Baatenburg de Jong RJ, Manni JJ, Marres HAM, Meeuwis CA, Lubsen H, Terhaard CHJ, Balm AJM.
• BOOK: Laryngotracheal Reconstruction - From Lab to Clinic P. Delaere Springer Verlag 2004. . 2004, XII, 298 p. 770 illus., 720 in color.

Abstracts

Top

Nucleaire

• European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358(9291):1421-3
• 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A. Eur J Cancer 2003;39(14):2012-20.
• Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, Deneffe GJ, Nackaerts KL, Verschakelen LA, Lerut TE, Mortelmans LA, Demedts MG. J ClinOncol 1998;16(6):2142-2149
• F-18]FDG PET monitoring of tumour response to chemotherapy: does [F-18]FDG uptake correlate with the viable tumour cell fraction? Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, Mortelmans L, Vandenberghe P, De Wolf-Peeters C. Eur J Nucl Med Mol Imaging 2003;30(5):682- 688.
• Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, Thomas J, Balzarini J, De Wolf- Peeters C, Mortelmans L, Verhoef G. Blood 2003;1:102(1):53-9.

Abstracts

Top

Oogziekten

• 18 Years’ experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma.Van Ginderdeuren R, Van Limbergen E, Spileers W. Br J Ophthalmol, 2005;89:1306-10.

Abstracts 

Pathologische ontleedkunde

Borstpathologie

• Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/ neu overexpression in human breast carcinomas. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C. Histopathology 2005;46(4):431-41.
• Comparative Expressed Sequence Hybridisation revealed differential gene expression in morphological breast cancer subtypes. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, De Wolf-Peeters C. J Pathol 2006;208:486-94.

Gastrointestinale pathologie

• Liver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammation.Schoonjans K, Dubuquoy L, Mebis J, Fayard E, Wendling O, Haby C, Geboes K, Auwerx J. Proc Natl Acad Sci USA 2005;102:2058-62.
•  Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas. Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N. Ann Surg. 2006;243:334- 340.

Hematopathologie

• Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. Warnke RA, Gatter KC, Falini B, Hildreth P, Woolston RE, Pulford K, Cordell JL, Cohen B, De Wolf-Peeters C, Mason DY. N Engl J Med 1983;309:1275-1281.
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. Blood 1994;84:1361-1392.

Huidpathologie

• A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Demunter A, Ahmadian RM, Libbrecht L, Stas M, Baens M, Scheffzek K, Degreef H, De Wolf-Peeters C, van den oord JJ. Cancer Res 2001;61(12):4916-4922.
• Gene expression profiling of primary cutaneous melanoma and clinical outcome. Winnemenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, otiz Romero PL, Roberto T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Trusz T, van den Oord JJ, Spatz A. J Natl Cancer Inst 2006;98:472-478.

Leverpathologie

• Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver.Vander Borght S, Libbrecht L, Blokzijl H, Faber KN, Moshage H, Aerts R, Van Steenbergen W, Jansen PL, Desmet VJ, Roskams T.  J Pathol. 2005;207(4):471-82.
• Identification of a novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells by a comparative functional genomic approach. Ju-Seog Lee, Jeonghoon Heo, Tania Roskams, Lewis R. Roberts, Frederik nevens, Louis Libbrecht, In-Sun Chu, Pal Kaposi-Novak, Anthony J. Demetris, Zongtang Sun, Diego F. Calvisi, Arsen Mikaelyan, Snorri S. Thorgeirsson. Nature Medicine 2006 in press.

Longpathologie

• Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, Verbeken EK, Bosmans H, Marchal G, Hermans R.  Radiol 2005;234(3):756-64.
• The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. BMC Cancer 2005;25;5(1):42.

Pathologie van de weke delen

• Local recurrence of myxofibrosarcoma is associated with increase in tumor grade and cytogenetic aberrations, suggesting a multistep tumor progression model. Willems S, Debiec-Rychter M, Karoly S, Hogendoorn PCW, Sciot R. Modern Pathology 2006;19:407-416.
• Molecular Pathogenesis of Multiple Gastrointestinal Stromal Tumors in NF1 patients. Maertens O, Prenen H, Debiec-Rychter M, Sciot R, Pauwels P, Wozniak A, De Paepe A, Speleman F, Mesiaen L, Legius E. Human Molecular Genetics 2006;15:1015- 1023.

Radiologie

• Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, Verschakelen JA. European Radiology, 2006 May 9.
• Evaluation of the larynx for tumour recurrence by diffusion weighted MRI after radiotherapy: initial experience in four cases. Vandecaveye V, De Keyzer F, Vander Poorten V, Deraedt K, Alaerts H, Landuyt W, Nuyts S, Hermans R. Br J Radiology 2006 April 26.
• Intrahepatic mitomycin C as treatment of breast cancer hepatic metastases. Demey W, Wildiers H, Maleux G, Heye S, Clement P, Debruyne P, Van Oosterom A, Paridaens R.Oral presentation at BSMO, 2006 February 4.
• Dry preparation for virtual CT colonography with faecal tagging using watersoluble contrast medium: initial results. Bielen D, Thomeer M, Vanbeckevoort D, Kiss G, Maes F, Marchal G, Rutgeerts P. Eur Rad 2003;13:453–458. 
• Clinical validation of high-resolution fast spin-echo MR colonography after colon distention with air. Bielen DJ, Bosmans HT, De Wever LL, Maes F, Tejpar S, Vanbeckevoort D, Marchal GJ. J Magn Reson Imaging 2005;22:400-405.

Abstracts

Top

Radiotherapie

• Towards videncebased guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Bentzen S, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, Van den Bogaert W.Radiother Oncol 2005;75,355-365.
• A new approach to the validation of tissue microarrays. Goethals L, Perneel C, Debucquoy A, De Schutter H, Borghys D, Ectors N, Geboes K, McBride WH, Haustermans KM.J Pathol 2006;208:607-614.
• Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer. Bussels B, Maes A, Hermans R, Nuyts S, Weltens C, Van den Bogaert W. 
• Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. Bartelink H, Horiot JC, Poortmans Ph, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M. N Engl J Med 2001;345:1378-1387.
• Is there a role for FDG-PET in radiotherapy planning in esophageal carcinoma? Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, Hiele M, Van den Bogaert W, Flamen P. Radiother Oncol 2004;73(3):269-75.

Abstracts

Top

Respiratoire oncologie

• Lymph node staging in non-small cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. Vansteenkiste JF, Stroobants SG, De Leyn PR, Bogaert J, Dupont PJ, Maes A, Deneffe GJ, Nackaerts KL, Verschakelen JA, Lerut TE, Mortelmans LA, Demedts MG. J Clin Oncol 1998;16:2142-2149.
• Prognostic importance of the Standardized Uptake Value on FDG-PET-scan in non-small cell lung cancer: An analysis of 125 cases. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK, Deneffe GJ, Mortelmans LA, Demedts MG, The Leuven Lung Cancer Group. J Clin Oncol 1999;10:3201-3206.
• Doubleblind, placebo-controlled, randomized phase 3 trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Vansteenkiste J, Pirker R, Massuti B, Barata F, Rosell R, Gastl G, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, ARANESP 980297 Study Group. J Natl Cancer Inst 2002;94:1211- 1220.
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. The International Adjuvant Lung Cancer Trial Collaborative Group, by Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J.N Engl J of Med 2004;350:351-360.
• Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Lancet Oncol 2004;5:531-540.

Abstracts

Top

Thoraxheelkunde

• Prospective comparative study of integrated PETCT versus re-mediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy proven stage IIIa-N2 non-small cell lung cancer. De Leyn P, Stroobants S, De Wever W, Lerut T, Coosemans W, Decker G, Nafteux P, Van Raemdonck D, Mortelmans L, Nackaerts K, Vansteenkiste J. A Leuven Lung Cancer Group Study. JCO 2006, in Press (publication date July 2006). J Clin Oncol 2006;24:3333-9.
• Histopathologic Validation of Lymphnode Staging with FDG-PET-scan in Cancer of the Esophagus and Gastroesophageal Junction. Lerut A, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M, De Wever W, Coosemans W, Decker G, De Leyn P, Deneffe G, Van Raemdonck D, Mortelmans L. Ann Surg 2000;232(6):743-752.
• Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastro-esophageal junction. Lerut T, Coosemans W, Decker G, De Leyn P, Ectors N, Fieuws S, Moons J, Nafteux P, Van Raemdonck D and the Leuven Collaborative Workgroup for Esophageal Carcinoma. J Thorac Cardiovasc Surg 2003;126(4):1121 – 1128. Three-field lypmhadenectomy for carcinoma of the esophagus and gastro-esophageal junction in 174 R0 resections.
• Impact on TNM staging and outcome. Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Moons J, Van Raemdonck D. Ann Surg 2004;240(6):962-972.
• Results of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy. De Leyn P, Vansteenkiste J, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Eur J Cardiothorac Surg 1999;15(5):608-614. Three-field lypmhadenectomy for carcinoma of the esophagus and gastro-esophageal junction in 174 R0 resections.

Abstracts

Top

Urologie

• European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Bolla M, Van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Marechal JM, Scalliet P, Haustermans K, Pierart M. Lancet 2005;366(9485):572-8.
• Radical prostatectomy for locally advanced prostate cancer: Results of a feasibility study (EORTC 30001). Van Poppel H, Vekemans K, Da Pozzo L, Bono A, Kliment J, Montironi R, Debois M, Collette L. Eur J Cancer 2006;42(8):1062-7. Epub 2006 Apr 18.
• Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. Van Poppel H, Vandendriessche H, Boel K, Mertens V, Goethuys H, Haustermans K, Van Damme B, Baert L. J Urol 1997;158(1):45-9.
• Clinical experience with the N-shaped ileal neobladder: assessment of complications, voiding patterns, and quality of life in our series of 58 patients. Joniau S, Benijts J, Van Kampen M, De Waele M, Ooms J, Van Cleynenbreugel B, Van Poppel H. Eur Urol 2005;47(5):666-72; discussion 672-3. Epub 2005 Jan 20. 
• The indications for partial nephrectomy in the treatment of renal cell carcinoma.Joniau S, Vander Eeckt K, Van Poppel H. Nat Clin Pract Urol 2006;3(4):198- 205. 
• Effect of pelvic-floor reeducation on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. Van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert L. Lancet. 2000 Jan 8;355(9198):98-102. 

Abstracts

Top

Fysische geneeskunde en revalidatie

• Stroke rehabilitation in Europe: what do physiotherapists and occupational therapists actually do? De Wit L, Putman K, Lincoln N, Baert I, Berman P, Beyens H, et al. Stroke 2006;37(6):1483-9. Epub 2006 Apr 27.
• Effect of simulator training on driving after stroke: a randomized controlled trial. Akinwuntan AE, De Weerdt W, Feys H, Pauwels J, Baten G, Arno P, Kiekens C. Neurology 2005;65(6):843-50. Summary for patients in: Neurology 2005;65(6):E13-4.
• The validity of a road test after stroke. Akinwuntan AE, De Weerdt W, Feys H, Baten G, Arno P, Kiekens C. Arch Phys Med Rehabil 2005;86(3):421-6.
• Early and repetitive stimulation of the arm can substantially improve the long-term outcome after stroke: a 5-year follow-up study of a randomized trial. Feys H, De Weerdt W, Verbeke G, Steck GC, Capiau C, Kiekens C, Dejaeger E, Van Hoydonck G, Vermeersch G, Cras P. Stroke 2004;35(4):924-9. Epub 2004 Mar 4.
• Case report and review of the literature. Steenberghs J, Kiekens C, Menten J, Monstrey J. Intradural chordoma without bone involvement. J Neurosurg 2002;97(1 Suppl):94-7. Review.

Abstracts 

Top

Laboratoriumgeneeskunde

• Fusion gene and Ig/TCR gene rearrangements are complementary but infrequent targets for PCRbased detection of minimal residual disease in acute myeloid leukaemia. Boeckx N, Willemse M, Szscepanski T, Langerak TW, van der Velden VHJ, Vandekerckhove P, van Dongen JJM. Leukemia 2002;16:368-375.
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJM. Leukemia 2003;17: 1-40.
• Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using realtime quantitative reverse transcription-PCR. Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Wildiers H, Omar S, Vandekerckhove P, Van Oosterom AT. Clin Cancer Res 2004;10:196-201.
• Detection of minimal residual disease in acute leukemia. van der Velden VHJ, Boeckx N, van Wering ER, van Dongen JJM. Review. J Biol Regul Homeost Agents 2004;18:146-154.
• High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients. van der Velden VHJ, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M, van Dongen JJM. Leukemia 2004;18:983-988.

Abstracts

Top

Psychiatrie en psychologie

• New evidence on the reliability and validity of the Pediatric Oncology Quality of Life Scale. Bijttebier P, Vercruysse T, Vertommen H, Van Gool S, Uyttebroeck A, Brock P. Psychology and Health 2001;16:461-469.
• Predictieve genetische tests en hun psychologische betekenis. Evers-Kiebooms G. Die ziekte in mijn familie, krijg ik die later ook? Raymaekers B, Van Riel G. (Eds)
• Attention and information processing in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy only. Mennes M, Stiers P, Vandenbussche E, Vercruysse G, Uyttebroeck A, De Meyer G, Van Gool SW. Pediatr Blood Cancer 2005;44:479-486.
• Opvang van familiale beenmergdonoren binnen de kinderoncologie: hoe ver staan wij? Vercruysse T. Oncologisch tijdschrift 2001;18(4):57-59.

Abstracts

Top